Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Carducci

Showing results (241-250 of 386) with videos related to

Pageof 39
Sort By:
Cancer Chemotherapy and Pharmacology|November 17, 2001
Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumorsE I Heath, S O'Reilly, R Humphrey, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2012
Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinomaDaniel Keizman, Maya Ish-Shalom, Roberto Pili, et al.
The Journal of Urology|November 25, 2015
A Retrospective Analysis of the Effect on Survival of Time from Diagnosis to Neoadjuvant Chemotherapy to Cystectomy for Muscle Invasive Bladder CancerJong Chul Park, Nilay M Gandhi, Michael A Carducci, et al.
Cancer Medicine|December 21, 2022
Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT studySusan Eggly, Nicole Senft, Seongho Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancerElisabeth I Heath, David W Hillman, Ulka Vaishampayan, et al.
Biorxiv : the Preprint Server for Biology|February 26, 2024
CRM1 regulates androgen receptor stability and impacts DNA repair pathways in prostate cancer, independent of the androgen receptorRajendra Kumar, Janet Mendonca, Abhishek Shetty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2006
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancerMichael A Carducci, Luna Musib, Merrill S Kies, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 28, 2025
CRM1 regulates androgen receptor stability and impacts DNA repair pathways in prostate cancer, independent of the androgen receptorRajendra Kumar, Janet Mendonca, Abhishek Shetty, et al.
European Urology|October 9, 2018
Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene DefectsPedro Isaacsson Velho, Fahad Qazi, Sayeedul Hassan, et al.
Hepato-Gastroenterology|March 18, 2011
High serum resistin in chronic viral hepatitis is not a marker of metabolic disorderC Morace, A Spadaro, M Cucunato, et al.
Pageof 39

Showing results (241-250 of 386) with videos related to

Sort By:
Pageof 39
Cancer Chemotherapy and Pharmacology|November 17, 2001
Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumorsE I Heath, S O'Reilly, R Humphrey, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2012
Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinomaDaniel Keizman, Maya Ish-Shalom, Roberto Pili, et al.
The Journal of Urology|November 25, 2015
A Retrospective Analysis of the Effect on Survival of Time from Diagnosis to Neoadjuvant Chemotherapy to Cystectomy for Muscle Invasive Bladder CancerJong Chul Park, Nilay M Gandhi, Michael A Carducci, et al.
Cancer Medicine|December 21, 2022
Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT studySusan Eggly, Nicole Senft, Seongho Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancerElisabeth I Heath, David W Hillman, Ulka Vaishampayan, et al.
Biorxiv : the Preprint Server for Biology|February 26, 2024
CRM1 regulates androgen receptor stability and impacts DNA repair pathways in prostate cancer, independent of the androgen receptorRajendra Kumar, Janet Mendonca, Abhishek Shetty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2006
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancerMichael A Carducci, Luna Musib, Merrill S Kies, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 28, 2025
CRM1 regulates androgen receptor stability and impacts DNA repair pathways in prostate cancer, independent of the androgen receptorRajendra Kumar, Janet Mendonca, Abhishek Shetty, et al.
European Urology|October 9, 2018
Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene DefectsPedro Isaacsson Velho, Fahad Qazi, Sayeedul Hassan, et al.
Hepato-Gastroenterology|March 18, 2011
High serum resistin in chronic viral hepatitis is not a marker of metabolic disorderC Morace, A Spadaro, M Cucunato, et al.
Pageof 39